摘要
目的研究c—erbB-2和nm23蛋白在乳腺癌中的表达。方法应用免疫组化S—P法，检测107例乳腺癌c—erbB-2及nm23基因蛋白的表达，同时检测ER和PR。结果c—erbB-2和nm23蛋白表达的阳性率分别为62．6％和70．1％。c—erbB-2在浸润性导管癌中的阳性率达69％；nm23在浸润性小叶癌、鳞状细胞癌及大汗腺癌阳性表达为100％。c—erbB-2表达与患者的年龄、肿瘤体积、ER及PR无关，组间差异无显著性（P〉0．05）；而组织学分级组间差异有显著性（X^2=2．369，P=0．002），TNM分期之间差异有显著性（X^2=21，92，P=0．001）；在有无腋窝淋巴结转移方面组间差异有显著性（X^2=18．247，P=0．000）。nm23表达与患者的年龄、肿瘤体积无关，组间差异无显著性（P〉0．05）；TNM分期Ⅰ期与Ⅲ期之间差异有显著性（X^2=8．803，P=0．032）；在有无腋窝淋巴结转移方面组间差异有显著性（X^2=9．243，P=0．026）。c—erbB=2阳性率和表达强度与nm23阳性率和表达强度之间无明显关系（X^2=12．962，P=0．164）。结论c—erbB-2、nm23与ER、PR联合检测能较好地反映乳腺癌病理生物学特征。
Objective To study the expression of c - erbB - 2 and nm23 protein in breast cancer. Methods We used immunohistochemistry S - P method to examine the expression of c - erbB - 2 and nm23 protein in 107 breast cancer cases, and in the meantime examined the ER and PR. Results c - erbB - 2 had high expression in infiltrating ductal carcinoma and rim23 had high expression in infiltrating lobular carcinoma. The level of distinction between c - erbB -2 and histological classification, TNM clinical stages and lymph nodes metastasis had no relevance to the patients＇ages ,tumour sizes or the c -erbB -2 and nm23 expression, nm23 expression and TNM clinical stages were relevant to lymph nodes metastasis. The level of distinction between these two groups of indexes was not relevant to the patients age ,tumour size,histological classification or the c -erbB -2 and nm23 expression. There was no relevance between c - erbB - 2 expression and nm23 expression. Conclusion Combined examination of ER, PR, c - erbB - 2 and nm23 could well reflect the pathobiology characteristics of breast cancer.
出处
《医学新知》
CAS
2010年第4期279-281,284,共4页
New Medicine
